Positive perception of pharmacogenetic testing for psychotropic medications

Human Psychopharmacology

Volumn 29, Issue 3, 2014, Pages 287-291

  Lanktree, Matthew B ^a,b   Zai, Gwyneth ^c,d   Vanderbeek, Laura E ^e   Giuffra, Daniel E ^d   Smithson, David S ^a   Kipp, Lucas B ^a   Dalseg, Timothy R ^a   Speechley, Mark ^a   Kennedy, James L ^c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

antipsychotics; bioethics; genetics; pharmacogenetics; psychopharmacology

Indexed keywords

PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; CANADA; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; INFORMED CONSENT; MALE; PHARMACOGENETICS; PREJUDICE; QUESTIONNAIRE; SCHIZOPHRENIA; STUDENT; UNIVERSITY; YOUNG ADULT;

ADOLESCENT; ADULT; CANADA; FEMALE; GENETIC TESTING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MALE; PHARMACOGENETICS; PREJUDICE; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; STUDENTS; SURVEYS AND QUESTIONNAIRES; UNIVERSITIES; YOUNG ADULT;

EID: 84898803478     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2383     Document Type: Article

References (30)

1. American Psychiatric Association (APA). 2013. Clinical practice guidelines. http://www.psychiatry.org/practice/clinical-practice-guidelines (Accessed on 15 October 2013).
2. Bevan JL, Lynch JA, Dubriwny TN, et al,. 2003. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 5 (5): 393-399.
3. Botoseneanu A, Alexander JA, Banaszak-Holl J,. 2011. To test or not to test? The fole of attitudes, knowledge, and religious involvement among U.S. adults on intent-to-obtain adult genetic testing. Health Educ Behav 38 (6): 617-628.
4. Brandl EJ, Müller DJ, Hwang R, et al,. 2012. The AmpliChip(®) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarkers 16 (8): 897-903.
5. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H,. 2004. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 5 (9): 676-680.
6. Breckenridge A, Walley T,. 2008. Early access to new medicines. Clin Pharmacol Ther 84 (1): 23-25.
7. Corey-Lisle PK, Nash R, Stang P, Swindle R,. 2004. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 164 (11): 1197-1204.
8. Couzin J,. 2008. Science and commerce. Gene tests for psychiatric risk polarize researchers. Science 319 (5861): 274-277.
9. Fabbri C, Di Girolamo G, Serretti A,. 2013. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B (6): 487-520.
10. Fargher EA, Eddy C, Newman W, et al,. 2007. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8 (11): 1511-1519.
11. Haga SB, Burke W,. 2008. Pharmacogenetic testing: not as simple as it seems. Genet Med 10 (6): 391-395.
12. Haga SB, Tindall G, O'Daniel JM,. 2012. Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers 16 (3): 193-197.
13. Hoop JG, Lapid MI, Paulson RM, Roberts LW,. 2010. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 early adopting departments of psychiatry. J Clin Psychiatry 71 (6): 745-753.
14. IMS Institute for Healthcare Informatics. 2012. The use of medicines in the United States: review of 2011. http://www.imshealth.com/ims/Global/Content/ Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII-Medicines-in-U. S-Report-2011.pdf (Accessed on 15 October 2013).
15. Kato M, Serretti A,. 2008. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15 (5): 473-500.
16. Kessler RC, Chiu WT, Demler O, Walters EE,. 2005. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 62 (6): 617-627.
17. Kieling C, Baker-Henningham H, Belfer M, et al,. 2011. Child and adolescent mental health worldwide: evidence for action. Lancet 378 (9801): 1515-1525.
18. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ,. 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17 (3): 242-266.
19. MacGillivray S, Arroll B, Hatcher S, et al,. 2003. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326 (7397): 1014.
20. Malhotra AK, Correll CU, Chowdhury NI, et al,. 2012. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 69 (9): 904-912.
21. Masys D, Baker D, Butros A, Cowles KE,. 2002. Giving patients access to their medical records via the internet: the PCASSO experience. J Am Med Inform Assoc 9 (2): 181-191.
22. Morley KI, Hall WD,. 2004. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med 82 (1): 21-30.
23. Reynolds GP,. 2012. The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig 9 (1): 1-7.
24. Roses AD,. 2000. Pharmacogenetics and the practice of medicine. Nature 405 (6788): 857-865.
25. Serretti A, Kato M, Kennedy JL,. 2008. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 8 (2): 90-100.
26. Shuchman M, Hebert PC, Kale R, Sibbald B, Flegel K, MacDonald N,. 2008. Bringing a research base to psychiatry. CMAJ 178 (10): 1257-1260.
27. The International HapMap Consortium. 2010. Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58.
28. Vetti HH, Molven A, Eliassen AK, et al,. 2010. Is pharmacogenetic CYP2D6 testing useful? Tidsskr Nor Laegeforen 130: 2224-2228.
29. Wilde A, Meiser B, Mitchell PB, Schofield PR,. 2010. Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. Eur J Hum Genet 18 (1): 47-51.
30. World Health Organization (WHO). 2009. Global health risks: mortality and burden of disease attributable to selected major risks. WHO Press, Geneva, Switzerland. http://www.who.int/healthinfo/global-burden-disease/ GlobalHealthRisks-report-full.pdf (Accessed on 15 October 2013).